Avian Influenza Virus HA antibody and antigen (recombinant protein)
Diagnostic anti-Avian Influenza Virus HA antibodies pairs and antigen for animal health (animal Avian/Bird/Poultry infectious disease Avian influenza) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT
Go to Avian/Bird/Poultry disease testing products collection >>
Product information
Catalog No. | Description | US $ Price (per mg) |
---|---|---|
GMP-VT-P175-Tg002-Ag01 | Recombinant Avian Influenza Virus HA protein | $3090.00 |
GMP-VT-P175-Tg002-Ab01 | Anti-Avian Influenza Virus HA mouse monoclonal antibody (mAb) | $3090.00 |
GMP-VT-P175-Tg002-Ab02 | Anti-Avian Influenza Virus HA mouse monoclonal antibody (mAb) | $3090.00 |
GMP-VT-P175-Tg002-Ab03 | Anti-Avian Influenza Virus HA human monoclonal antibody (mAb) | $3090.00 |
GMP-VT-P175-Tg002-Ab04 | Anti-Avian Influenza Virus HA human monoclonal antibody (mAb) | $3090.00 |
Size: 1mg | 10mg | 100mg
Product Description
Cat No. | GMP-VT-P175-Tg002-Ag01 |
Product Name | Recombinant Avian Influenza Virus HA protein |
Pathogen | Avian Influenza Virus |
Expression platform | E.coli |
Isotypes | Recombinant Antigen |
Bioactivity validation | Anti-Avian Influenza Virus HA antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Avian Influenza Virus level test of animal Avian/Bird/Poultry infectious disease with Avian influenza. |
Tag | His | Product description | Recombinant Avian Influenza Virus HA proteinwas expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Cat No. | GMP-VT-P175-Tg002-Ab01,GMP-VT-P175-Tg002-Ab02 |
Pathogen | Avian Influenza Virus |
Product Name | Anti-Avian Influenza Virus HA mouse monoclonal antibody (mAb) |
Expression platform | CHO |
Isotypes | Mouse IgG |
Bioactivity validation | Recombinant Avian Influenza Virus HA antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Avian Influenza Virus antibodies in Avian Influenza Virus level test of animal Avian/Bird/Poultry infectious disease with Avian influenza. |
Product description | Anti-Avian Influenza Virus HA mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Avian Influenza Virus antibodies. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Cat No. | GMP-VT-P175-Tg002-Ab03,GMP-VT-P175-Tg002-Ab04 |
Pathogen | Avian Influenza Virus |
Product Name | Anti-Avian Influenza Virus HA human monoclonal antibody (mAb) |
Expression platform | CHO |
Isotypes | Human lgG1 |
Bioactivity validation | Recombinant Avian Influenza Virus HA antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Avian Influenza Virus antibodies in Avian Influenza Virus level test of animal Avian/Bird/Poultry infectious disease with Avian influenza. |
Product description | Anti-Avian Influenza Virus HA mouse monoclonal antibody (mAb) is a human monoclonal antibody produced by CHO. The antibody is ELISA validated as capture antibody and detection antibody pair. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Validation Data
Click to get more Data / Case study about the product.
Pathogen Information
Avian Influenza Virus (AIV) is a highly contagious pathogen that primarily infects birds, including domesticated poultry such as chickens, ducks, and turkeys, as well as wild birds. The virus can also infect humans and other mammals, such as pigs and ferrets, leading to concerns about its potential for zoonotic transmission. AIV is classified within the Orthomyxoviridae family, which also includes the influenza viruses that cause seasonal flu in humans.
The genome of AIV consists of eight single-stranded RNA segments, each of which encodes for different viral proteins. Two of the most important proteins are hemagglutinin (HA) and neuraminidase (NA), which are found on the surface of the virus. The HA protein allows the virus to attach to host cells by binding to specific receptors on the cell membrane, while the NA protein cleaves sialic acid molecules on the surface of the infected cell to facilitate virus release. These viral proteins are also the primary targets for immune responses mounted by the host.
AIV is classified as a type A influenza virus, which has been categorized into different subtypes based on the antigenic properties of the HA and NA proteins. To date, 18 different HA subtypes and 11 different NA subtypes have been identified in avian populations, giving rise to a diversity of AIV strains. This genetic variability enables AIV to evolve quickly and adapt to new hosts, leading to the emergence of new strains with pandemic potential.
In birds, AIV can cause a range of clinical signs and symptoms, depending on the virulence of the strain and the species affected. Some birds may show no obvious signs of infection, while others may develop mild respiratory symptoms such as coughing, sneezing, and nasal discharge. In more severe cases, birds may exhibit neurological symptoms, such as tremors, ataxia, and paralysis, and can die within hours of infection. AIV can also cause systemic infection, leading to damage to internal organs and death.
AIV infection in humans is relatively rare but can occur through exposure to infected birds or contaminated environments, such as live bird markets or poultry farms. Human cases of AIV are typically associated with close contact with infected birds or their excreta, and the risk of transmission is generally low. However, some AIV strains, such as H5N1 and H7N9, have been associated with severe respiratory illness and a high mortality rate in humans, leading to concerns about their pandemic potential.
To detect AIV infection, various diagnostic methods are available, including nucleic acid tests, virus isolation, and serological assays. Nucleic acid tests, such as RT-PCR, are highly sensitive and specific and can detect viral RNA in clinical samples such as blood, swabs, and feces. Virus isolation involves culturing the virus from clinical samples in cell culture or embryonated eggs, while serological assays measure the presence of antibodies against AIV in blood samples. These diagnostic methods can also differentiate between different AIV subtypes and strains, providing valuable information for disease surveillance and outbreak monitoring.
In conclusion, AIV is a highly contagious pathogen that primarily infects birds but can also infect humans and other animals. The virus has the potential to cause severe illness and death in both birds and humans, and its genetic variability and pandemic potential make it a significant public health concern. Timely detection and prompt control measures are essential for preventing and managing AIV outbreaks.
About GDU
GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.